- Home
- SATL vs ARCT Comparison
SATL vs ARCT Comparison
Compare SATL & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SATL
- ARCT
- Stock Information
- Founded
- SATL 2010
- ARCT 2013
- Country
- SATL United States
- ARCT United States
- Employees
- SATL N/A
- ARCT N/A
- Industry
- SATL Radio And Television Broadcasting And Communications Equipment
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- SATL Technology
- ARCT Health Care
- Exchange
- SATL Nasdaq
- ARCT Nasdaq
- Market Cap
- SATL 373.7M
- ARCT 320.8M
- IPO Year
- SATL N/A
- ARCT N/A
- Fundamental
- Price
- SATL $3.77
- ARCT $20.52
- Analyst Decision
- SATL
- ARCT Strong Buy
- Analyst Count
- SATL 0
- ARCT 9
- Target Price
- SATL N/A
- ARCT $50.88
- AVG Volume (30 Days)
- SATL 2.4M
- ARCT 829.2K
- Earning Date
- SATL 11-12-2025
- ARCT 11-06-2025
- Dividend Yield
- SATL N/A
- ARCT N/A
- EPS Growth
- SATL N/A
- ARCT N/A
- EPS
- SATL N/A
- ARCT N/A
- Revenue
- SATL $13,868,000.00
- ARCT $122,122,000.00
- Revenue This Year
- SATL N/A
- ARCT N/A
- Revenue Next Year
- SATL N/A
- ARCT $28.92
- P/E Ratio
- SATL N/A
- ARCT N/A
- Revenue Growth
- SATL 1.09
- ARCT N/A
- 52 Week Low
- SATL $0.93
- ARCT $8.04
- 52 Week High
- SATL $5.49
- ARCT $24.13
- Technical
- Relative Strength Index (RSI)
- SATL 54.32
- ARCT 54.94
- Support Level
- SATL $3.45
- ARCT $20.21
- Resistance Level
- SATL $3.85
- ARCT $23.60
- Average True Range (ATR)
- SATL 0.22
- ARCT 1.64
- MACD
- SATL 0.02
- ARCT -0.07
- Stochastic Oscillator
- SATL 55.19
- ARCT 44.74
About SATL Satellogic Inc.
Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.